[go: up one dir, main page]

PE20090991A1 - Forma galenica divisible que permite una liberacion modificada del principio activo - Google Patents

Forma galenica divisible que permite una liberacion modificada del principio activo

Info

Publication number
PE20090991A1
PE20090991A1 PE2008001421A PE2008001421A PE20090991A1 PE 20090991 A1 PE20090991 A1 PE 20090991A1 PE 2008001421 A PE2008001421 A PE 2008001421A PE 2008001421 A PE2008001421 A PE 2008001421A PE 20090991 A1 PE20090991 A1 PE 20090991A1
Authority
PE
Peru
Prior art keywords
divisible
cellulose
active principle
modified release
allows
Prior art date
Application number
PE2008001421A
Other languages
English (en)
Inventor
Gilles Fonknechten
Jean-Manuel Pean
Patrick Genty
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090991(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20090991A1 publication Critical patent/PE20090991A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE REFIERE A UNA FORMA GALENICA DIVISIBLE, POR EJEMPLO UN COMPRIMIDO DIVISIBLE, DE LIBERACION MODIFICADA QUE COMPRENDE UNO O VARIOS PRINCIPIOS ACTIVOS Y LOS SIGUIENTES EXCIPIENTES: UN POLIMERO DERIVADO DE CELULOSA, TAL COMO HIDROXIMETILCELULOSA, HIDROXIETILCELULOSA, HIDROXIPROPILCELULOSA E HIDROXIPROPILMETILCELULOSA, Y UN AGLUTINANTE, TAL COMO MALTODEXTRINA, POLIVIDONA O HIDROXIPROPILMETILCELULOSA DE MUY BAJA VISCOSIDAD. DICHA FORMA GALENICA SE CARACTERIZA POR EL HECHO DE QUE PRESENTA UN PERFIL DE DISOLUCION QUE ES IDENTICO SE HAYA SUBDIVIDIDO O NO. POR EJEMPLO, EL COMPRIMIDO DIVISIBLE DE LIBERACION PROLONGADA EN SU FORMA NO SUBDIVIDIDA Y UNA FRACCION DE DICHA FORMA OBTENIDA POR SUBDIVISION, TIENEN UN PERFIL DE DISOLUCION IDENTICO. DE MANERA PREFERIDA, EL PRINCIPIO ACTIVO QUE COMPRENDE LA PRESENTE INVENCION ES LA GLICAZIDA
PE2008001421A 2008-03-21 2008-08-22 Forma galenica divisible que permite una liberacion modificada del principio activo PE20090991A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
PE20090991A1 true PE20090991A1 (es) 2009-07-18

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001421A PE20090991A1 (es) 2008-03-21 2008-08-22 Forma galenica divisible que permite una liberacion modificada del principio activo

Country Status (35)

Country Link
US (3) US20090238870A1 (es)
EP (2) EP3025706A1 (es)
JP (2) JP5231906B2 (es)
KR (3) KR20090101048A (es)
CN (1) CN101347414B (es)
AP (1) AP2729A (es)
AR (1) AR067993A1 (es)
AU (1) AU2008207680B8 (es)
CA (1) CA2629670C (es)
CL (1) CL2008002486A1 (es)
CO (1) CO6020017A1 (es)
CR (2) CR10317A (es)
CU (1) CU23970B1 (es)
EA (1) EA200801862A1 (es)
EC (1) ECSP088727A (es)
FR (1) FR2928836B1 (es)
GT (1) GT200800163A (es)
HN (1) HN2008001466A (es)
IL (1) IL193611A0 (es)
JO (1) JO3052B1 (es)
MA (1) MA31218B1 (es)
ME (1) ME01031B (es)
MX (1) MX2008011579A (es)
MY (1) MY150660A (es)
NI (1) NI200800256A (es)
NZ (1) NZ570715A (es)
PE (1) PE20090991A1 (es)
SA (1) SA08290555B1 (es)
SG (1) SG155819A1 (es)
SV (1) SV2008003023A (es)
TW (1) TWI396561B (es)
UA (1) UA86731C2 (es)
UY (1) UY31307A1 (es)
WO (1) WO2009125087A1 (es)
ZA (1) ZA200807354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8795723B2 (en) 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
ES3010208T3 (en) 2020-03-16 2025-04-01 Gruenenthal Gmbh Scored tablet comprising tapentadol

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
EP1063973B1 (en) * 1998-03-19 2016-11-16 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
ATE387905T1 (de) * 1998-04-03 2008-03-15 Kyowa Hakko Kogyo Kk Teilbare tablette und durchdrückpackung
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
ES2255490T3 (es) * 1999-03-31 2006-07-01 Janssen Pharmaceutica N.V. Almidon pregelatinizado en una formulacion de liberacion controlada.
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
EP2074992B1 (en) * 2005-04-08 2015-05-20 Abbott Laboratories Oral pharmaceutical formulations comprising salts of fenofibric acid
KR20080034517A (ko) * 2005-08-18 2008-04-21 데이진 화-마 가부시키가이샤 정확한 용량 분할 기능을 갖는 제제
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
US8795723B2 (en) * 2005-09-09 2014-08-05 Angelini Pharma Inc. Sustained drug release compositions
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
MX2009001429A (es) * 2006-08-10 2009-02-17 Takeda Pharmaceutical Composicion farmaceutica.
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
BRPI0803631A2 (pt) 2011-03-29
SV2008003023A (es) 2010-07-29
NZ570715A (en) 2010-10-29
UA86731C2 (ru) 2009-05-12
AU2008207680B2 (en) 2010-04-22
WO2009125087A1 (fr) 2009-10-15
UY31307A1 (es) 2008-10-31
KR20110112266A (ko) 2011-10-12
KR20090101048A (ko) 2009-09-24
CL2008002486A1 (es) 2008-12-26
ZA200807354B (en) 2008-11-26
MA31218B1 (fr) 2010-03-01
AU2008207680B8 (en) 2010-05-13
ECSP088727A (es) 2008-10-31
JP5231906B2 (ja) 2013-07-10
IL193611A0 (en) 2009-08-03
AP2729A (en) 2013-08-31
EP3025706A1 (fr) 2016-06-01
CN101347414A (zh) 2009-01-21
MY150660A (en) 2014-02-14
AP2008004614A0 (en) 2008-10-31
CA2629670A1 (fr) 2008-10-01
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
FR2928836A1 (fr) 2009-09-25
US20140221449A1 (en) 2014-08-07
SG155819A1 (en) 2009-10-29
ME01031B (me) 2012-10-20
EA200801862A1 (ru) 2009-10-30
JP2009227651A (ja) 2009-10-08
US20090238870A1 (en) 2009-09-24
HK1127280A1 (en) 2009-09-25
CU20080179A7 (es) 2011-04-26
CR20140334A (es) 2014-08-20
KR20150035829A (ko) 2015-04-07
NI200800256A (es) 2010-02-11
KR101693189B1 (ko) 2017-01-05
CR10317A (es) 2008-11-26
CU23970B1 (es) 2013-12-27
FR2928836B1 (fr) 2011-08-26
CA2629670C (fr) 2012-04-17
TW200940109A (en) 2009-10-01
JP2010209103A (ja) 2010-09-24
JO3052B1 (ar) 2017-03-15
HN2008001466A (es) 2011-04-25
CO6020017A1 (es) 2009-03-31
US20130295176A1 (en) 2013-11-07
CN101347414B (zh) 2011-11-23
TWI396561B (zh) 2013-05-21
EP2103302A1 (fr) 2009-09-23
GT200800163A (es) 2010-05-21
MX2008011579A (es) 2009-09-21
SA08290555B1 (ar) 2011-07-20

Similar Documents

Publication Publication Date Title
PE20090991A1 (es) Forma galenica divisible que permite una liberacion modificada del principio activo
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
UY32389A (es) Composición farmacéutica sólida que comprende amlodipina y losartan con estabilidad mejorada
UY32793A (es) Compuestos inhibidores de los virus flaviviridae, composición farmacéutica que los contiene y sus usos
AR089931A1 (es) Composiciones farmaceuticas que contienen dimetilfumarato
NI201500030A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
EP2913323A4 (en) FLUORESCENT, PHOTOPOLYMERIZATION INITIATOR USING THIS FLUORENE COMPOUND AND LIGHT SENSITIVE COMPOSITION USING THIS PHOTOPOLYMERIZATION INITIATOR
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
EA033811B1 (ru) Стабильные бесконсервантные мидриатические и противовоспалительные растворы для инъекций
CU20150071A7 (es) Composición de liberación demorada que comprende biguanida
LT3360575T (lt) Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus
CR20110611A (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil) acetato de 4-(dimetilamino)butilo
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
BR112015009603A2 (pt) novos derivados de pirazina
CO2018002045A2 (es) Derivados de 2-amino-nicotinamida y 3-amino-pirazin-2-carboxamida
BR112014010047A2 (pt) novos derivados de pirazina
BR112014012521A2 (pt) novos derivados de pirrolidina como inibidores de catepsina
CL2014000484A1 (es) Compuestos derivados del acido pirrolidin-3-il-acetico; composicion farmaceutica que los comprende y uso en el tratamiento de la enfermedad inflamatoria del intestino.
CL2011002619A1 (es) Compuestos derivados de arilsulfonamidas, moduladores de la actividad del receptor ccr3; composición farmacéutica que los comprende; utiles en el traramiento de una enfermedad inflamatoria tal como asma, rinitis alergica, dermatitis atopica, epoc entre otras.
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
UA119441C2 (uk) Посилювачі водорозчинності на основі глікогену
CL2014002430A1 (es) Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88.
CL2013003536A1 (es) Compuestos derivados de 4-fenil indazol y 4-fenil-ciclopentapirazol, inhibidores de aldosterona sintasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades del riñon, tales como enfermedad renal cronica y nefropatia diabetica.
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration